Sodium-glucose co-transporter 2 (SGLT2) inhibitors (Formulary)

DAPAGLIFLOZIN

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Tablets 5mg, 10mg (specialist initiation)

Dosage:

  • SMC2322: in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.

Editorial Information

Document Id: F047